View Filing Data

Print Document View Excel Document

DOCUMENT AND ENTITY INFORMATION - shares	3 Months Ended
DOCUMENT AND ENTITY INFORMATION - shares	Mar. 31, 2019	May 10, 2019
Document and Entity Information
Entity Registrant Name	YIELD10 BIOSCIENCE, INC.
Entity Central Index Key	0001121702
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus (i.e. Q1,Q2,Q3,FY)	Q1
Amendment Flag	false
Entity Common Stock, Shares Outstanding		12,494,731

CONDENSED CONSOLIDATED BALANCE SHEETS UNAUDITED - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Current Assets:
Cash and cash equivalents	$ 6,065	$ 3,023
Short-term investments	0	2,746
Accounts receivable	45	94
Unbilled receivables	79	66
Prepaid expenses and other current assets	549	448
Total current assets	6,738	6,377
Restricted cash	332	332
Property and equipment, net	1,335	1,385
Right-of-use assets	4,619	4,766
Other assets	71	100
Total assets	13,095	12,960
Current Liabilities:
Accounts payable	12	117
Accrued expenses	621	680
Lease liabilities	869	844
Total current liabilities	1,502	1,641
Lease liabilities, net of current portion	5,398	5,621
Total liabilities	6,900	7,262
Commitments and contingencies (Note 9)
Stockholders’ Equity:
Preferred Stock ($0.01 par value per share); 5,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock ($0.01 par value per share); 60,000,000 shares authorized at March 31, 2019 and December 31, 2018; 12,468,219 and 10,025,811 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively	125	100
Additional paid-in capital	360,383	357,646
Accumulated other comprehensive loss	(115)	(110)
Accumulated deficit	(354,198)	(351,938)
Total stockholders’ equity	6,195	5,698
Total liabilities and stockholders’ equity	$ 13,095	$ 12,960

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS UNAUDITED - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Revenue:
Revenue	$ 124	$ 60
Expenses:
Research and development	1,223	1,101
General and administrative	1,186	1,276
Total expenses	2,409	2,377
Loss from operations	(2,285)	(2,317)
Other income (expense), net	25	25
Net loss	$ (2,260)	$ (2,292)
Basic and diluted net loss per share (in USD per share)	$ (0.22)	$ (0.24)
Number of shares used in per share calculations:
Basic & Diluted (in shares)	10,503,291	9,698,726
Grant
Revenue:
Revenue	$ 124	$ 60

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value per share (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, authorized (in shares)	5,000,000	5,000,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0
Common stock, par value per share (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	60,000,000	60,000,000
Common stock, issued (in shares)	12,468,219	10,025,811
Common stock, outstanding (in shares)	12,468,219	10,025,811

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) UNAUDITED - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Statement of Comprehensive Income [Abstract]
Net loss:	$ (2,260)	$ (2,292)
Other comprehensive loss
Change in unrealized gain (loss) on investments	0	1
Change in foreign currency translation adjustment	(5)	(5)
Total other comprehensive loss	(5)	(4)
Comprehensive loss	$ (2,265)	$ (2,296)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS UNAUDITED - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities
Net loss	$ (2,260)	$ (2,292)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	50	47
Charge for 401(k) company common stock match	24	46
Stock-based compensation	162	281
Noncash lease expense	147	60
Changes in operating assets and liabilities:
Accounts receivables	49	12
Unbilled receivables	(13)	29
Prepaid expenses and other assets	(60)	(125)
Accounts payable	(105)	(27)
Accrued expenses	(92)	(993)
Lease liabilities	(198)	(68)
Net cash used for operating activities	(2,296)	(3,030)
Cash flows from investing activities
Purchase of property and equipment	0	(3)
Purchase of short-term investments	0	(4,002)
Proceeds from the sale and maturity of short-term investments	2,746	11
Net cash provided by (used for) investing activities	2,746	(3,994)
Cash flows from financing activities
Proceeds from warrants exercised	0	124
Proceeds from registered direct offering, net of issuance costs	2,597	0
Net cash provided by financing activities	2,597	124
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(5)	(4)
Net increase (decrease) in cash, cash equivalents and restricted cash	3,042	(6,904)
Cash, cash equivalents and restricted cash at beginning of period	3,355	14,804
Cash, cash equivalents and restricted cash at end of period	6,397	7,900
Supplemental disclosure of non-cash information:
Purchase of property and equipment included in accounts payable and accrued expenses	12	31
Offering costs remaining in accrued expenses	$ 14	$ 0

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Series B Warrant	Preferred Stock	Common Stock	Common Stock Series B Warrant	Additional Paid-In Capital	Additional Paid-In Capital Series B Warrant	Accumulated other Comprehensive Income (loss)	Accumulated Deficit
Balance at Dec. 31, 2017	$ 13,502		$ 818	$ 91		$ 355,431		$ (85)	$ (342,753)
Balance (in shares) at Dec. 31, 2017			1,826	9,089,159
Increase (decrease) in stockholders' equity
Non-cash stock-based compensation expense	281					281
Issuance of common stock for 401k match	22					22
Issuance of common stock for 401k match (in shares)				12,639
Issuance of common stock for registered direct offering		$ 124			$ 1		$ 123
Issuance of common stock for registered direct offering (in shares)					55,100
Issuance of common stock upon conversion of Series A Convertible Preferred Stock			$ (818)	$ 8		810
Issuance of common stock upon conversion of Series A Convertible Preferred Stock (in shares)			(1,826)	811,557
Effect of foreign currency translation and unrealized gain on investments	(4)							(4)
Net loss	(2,292)								(2,292)
Balance at Mar. 31, 2018	11,633		$ 0	$ 100		356,667		(89)	(345,045)
Balance (in shares) at Mar. 31, 2018			0	9,968,455
Balance at Dec. 31, 2018	$ 5,698		$ 0	$ 100		357,646		(110)	(351,938)
Balance (in shares) at Dec. 31, 2018	10,025,811		0	10,025,811
Increase (decrease) in stockholders' equity
Non-cash stock-based compensation expense	$ 162					162
Issuance of common stock for 401k match	17					17
Issuance of common stock for 401k match (in shares)				20,746
Issuance of common stock for registered direct offering	2,583			$ 25		2,558
Issuance of common stock for registered direct offering (in shares)				2,421,662
Effect of foreign currency translation and unrealized gain on investments	(5)							(5)
Net loss	(2,260)								(2,260)
Balance at Mar. 31, 2019	$ 6,195		$ 0	$ 125		$ 360,383		$ (115)	$ (354,198)
Balance (in shares) at Mar. 31, 2019	12,468,219		0	12,468,219

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) $ in Thousands	3 Months Ended
	Mar. 31, 2019 USD ($)
Statement of Stockholders' Equity [Abstract]
Issuance of common stock for registered direct offering, offering costs	$ 349

NATURE OF BUSINESS AND BASIS OF PRESENTATION	3 Months Ended
NATURE OF BUSINESS AND BASIS OF PRESENTATION	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF BUSINESS AND BASIS OF PRESENTATION	NATURE OF BUSINESS AND BASIS OF PRESENTATION Yield10 Bioscience, Inc. ("Yield10 Bioscience," "Yield10" or the "Company") is an agricultural bioscience company which uses its "Trait Factory" development process, which is a combination of the Company's unique background and expertise in metabolic modeling, genetic engineering, genome editing and next generation microbial gene systems, in order to develop high value seed traits for the agriculture and food industries. Specifically, Yield10 plans to efficiently develop superior gene traits for the major grain crops, which are: corn, soybean, canola, wheat and rice. The Company considers 10-20 percent increases in crop yield to be step-change increases. Yield10 is currently progressing several novel yield gene traits in its pipeline in canola, soybean and corn, the major North American row crops, among others. Over the last three years, the Company has evaluated certain of its traits in greenhouse studies and field tests conducted in the United States and Canada. Yield10 currently has two non-exclusive research license agreements in place with the Monsanto division of Bayer Crop Science, a division of Bayer AG, for the evaluation of the Company's C3003 and C3004 traits in soybean and with Forage Genetics International, LLC, a division of Land O'Lakes, Inc. for the evaluation of five yield traits in forage sorghum. The Company's business strategy is to progress its traits into field tests to generate validating yield data. Over the last three years, the Company has progressed its evaluation of C3003 in field test with Camelina and canola. Yield10 is planning to expand its field tests with additional traits and more events in 2019 and 2020. The Company plans to leverage data that it generates to support the performance of its traits in key crops to establish collaborations or sign licenses to the traits with major agricultural companies in order to generate revenue. Yield10 Bioscience is headquartered in Woburn, Massachusetts and has an oilseed development Center of Excellence in Saskatoon, Saskatchewan, Canada. The accompanying condensed consolidated financial statements are unaudited and have been prepared by Yield10 in accordance with accounting principles generally accepted in the United States of America ("GAAP") and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements have been condensed or omitted. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. The condensed consolidated financial statements, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) necessary for fair statements of the financial position and results of operations for the interim periods ended March 31, 2019 and March 31, 2018. The Company adopted Accounting Standards Update ("ASU") No. 2016-02, Leases, ("Topic 842") on January 1, 2019 using a modified retrospective approach. As a result, the Company's condensed consolidated balance sheet at December 31, 2018 and its condensed consolidated statements of operations, comprehensive income (loss), cash flows and stockholders' equity for the three months ending March 31, 2018, included herein, have been adjusted to incorporate the guidance of Topic 842. See Note 8. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for any future period or the entire fiscal year. These interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2018, which are contained in the Company’s Annual Report on Form 10-K filed with the SEC on March 28, 2019. The accompanying consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. With the exception of a single year, the Company has recorded losses since its initial founding, including the three months ending March 31, 2019. As of March 31, 2019, the Company held unrestricted cash and cash equivalents of $6,065. The Company follows the guidance of Accounting Standards Codification ("ASC") Topic 205-40, Presentation of Financial Statements-Going Concern, in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year after the date its financial statements are issued. Based on its current cash forecast management expects that the Company's present capital resources will be sufficient to fund its planned operations and meet its obligations into the fourth quarter of 2019. This forecast of cash resources is forward-looking information that involves risks and uncertainties, and the actual amount of expenses could vary materially and adversely as a result of a number of factors. The Company's ability to continue operations after its current cash resources are exhausted depends on its ability to obtain additional financing through, among other sources, public or private equity financing, secured or unsecured debt financing, equity or debt bridge financing, warrant holders' ability and willingness to exercise the Company's outstanding warrants, additional government grants or collaborative arrangements with third parties, as to which no assurance can be given. Management does not know whether additional financing will be available on terms favorable or acceptable to the Company when needed, if at all. If adequate additional funds are not available when required, management will be forced to curtail the Company's research efforts, explore strategic alternatives and/or wind down its operations and pursue options for liquidating its remaining assets, including intellectual property and equipment. Based on its cash forecast, management has determined that the Company's present capital resources will not be sufficient to fund its planned operations for the twelve months from the date that these financial statements are filed, which raises substantial doubt about the Company's ability to continue as a going concern. If the Company issues equity or debt securities to raise additional funds, (i) the Company may incur fees associated with such issuance, (ii) its existing stockholders may experience dilution from the issuance of new equity securities, (iii) the Company may incur ongoing interest expense and be required to grant a security interest in Company assets in connection with any debt issuance, and (iv) the new equity or debt securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders. In addition, utilization of the Company’s net operating loss and research and development credit carryforwards may be subject to significant annual limitations under Section 382 of the Internal Revenue Code of 1986 due to ownership changes resulting from equity financing transactions. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products or proprietary technologies or grant licenses on terms that are not favorable to the Company.

ACCOUNTING POLICIES

3 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

ACCOUNTING POLICIES

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies that the Company adopts as of the specified effective date. During the three months ended March 31, 2019, the Company adopted the following new accounting guidance.

In February 2016, the FASB issued ASU No. 2016-02, which requires lessees to recognize most leases on their balance sheet as right-of-use assets and lease liabilities. In July 2018, the FASB issued ASU No. 2018-10, "Codification Improvements to Topic 842, Leases" ("ASU 2018-10"), which provided narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU No. 2018-11, "Leases (Topic 842 - Targeted Improvements" ("ASU 2018-11"), which addressed implementation issues related to the new lease standard. The new guidance was effective for annual reporting periods beginning after December 15, 2018 and interim periods within those fiscal years, and early adoption was permitted. Under the new standard, disclosures are required to enable users of financial statements to better assess the amount, timing, and uncertainty of cash flows arising from leases. Topic 842 required filers to adopt the new standard using a modified retrospective approach under either of two transition methods; (1) to apply the new lease requirements at the beginning of the earliest period presented, or (2) to apply the new lease requirements at the effective date. The Company adopted the new standard on January 1, 2019 and elected to adjust its 2018 financial statements in order to make them comparable to its 2019 financial statements. Adoption of Topic 842 had a material impact on the Company's previously reported 2018 financial statements. See Note 8.

New pronouncements that are not yet effective but may impact the Company's financial statements in the future are described below.

In June 2016 the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. This standard will become effective for the Company on January 1, 2020, and requires adoption using a modified retrospective approach, with certain exceptions. Based on the composition of the Company's investment portfolio, current market conditions and historical credit loss activity, the adoption of this standard is not expected to have a material impact on the Company's consolidated financial position and results of operations and related disclosures.

In August 2018 the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. This standard modifies certain disclosure requirements on fair value measurements. This standard will become effective for the Company on January 1, 2020, and it is not expected that the adoption of this standard will have a material impact on the Company's disclosures.

In November 2018 the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606. This standard makes targeted improvements for collaborative arrangements as follows:

•

Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, Revenue from Contracts with Customers, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements;


•	Adds unit-of-account guidance to ASC 808, Collaborative Arrangements, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and


•	Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer.

This standard will become effective for the Company on January 1, 2020; however, early adoption is permitted. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings, as of January 1, 2019. The Company is currently evaluating the potential impact that this standard may have on its consolidated financial position, results of operations and related disclosures.

Principles of Consolidation

The Company's condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions were eliminated, including transactions with its Canadian subsidiary, Metabolix Oilseeds, Inc.

Cash, Cash Equivalents and Restricted Cash

The Company considers all highly liquid investments purchased with an original maturity date of ninety days or less at the date of purchase to be cash equivalents.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's Condensed Consolidated Unaudited Balance Sheets included herein:



	March 31, 2019		December 31, 2018
Cash and cash equivalents	$	6,065	$	3,023
Restricted cash	332		332
Total cash, cash equivalents and restricted cash	$	6,397	$	3,355

Amounts included in restricted cash represent those required to be set aside by contractual agreement. Restricted cash of $332 at March 31, 2019 and December 31, 2018 primarily consists of funds held in connection with the Company's lease agreement for its Woburn, Massachusetts facility.

Investments

The Company considers all investments purchased with an original maturity date of more than ninety days at the date of purchase and a maturity date of one year or less at the balance sheet date to be short-term investments. All other investments are classified as long-term. The Company held no short or long-term investments at March 31, 2019 and no long-term investments at December 31, 2018.

Other-than-temporary impairments of equity investments are recognized in the Company's statements of operations if the Company has experienced a credit loss and has the intent to sell the investment or if it is more likely than not that the Company will be required to sell the investment before recovery of the amortized cost basis. Realized gains and losses, dividends, interest income and declines in value judged to be other-than-temporary credit losses are included in other income (expense). Any premium or discount arising at purchase is amortized and/or accreted to interest income.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of grant revenue and expenses during the reporting periods. Actual results could differ from those estimates.

Foreign Currency Translation

Foreign denominated assets and liabilities of the Company's wholly owned foreign subsidiaries are translated into U.S. dollars at the prevailing exchange rates in effect on the balance sheet date. Revenues and expenses are translated at average exchange rates prevailing during the period. Any resulting translation gains or losses are recorded in accumulated other comprehensive income (loss) in the consolidated balance sheet. When the Company dissolves, sells or substantially sells all of the assets of a consolidated foreign subsidiary, the cumulative translation gain or loss of that subsidiary is released from comprehensive income (loss) and included within its consolidated statement of operations during the fiscal period when the dissolution or sale occurs.

Income Taxes

The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company's tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is provided to reduce the deferred tax asset to a level which, more likely than not, will be realized.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and investments. The Company has historically invested its cash equivalents in highly rated money market funds, corporate debt, federal agency notes and U.S. treasury notes. Investments, when purchased, are acquired in accordance with the Company’s investment policy which establishes a concentration limit per issuer.

At March 31, 2019, 100% of the Company's total accounts and unbilled receivables of $124 are due from U.S. government grants.

BASIC AND DILUTED NET INCOME (LOSS) PER SHARE

3 Months Ended

Mar. 31, 2019

Earnings Per Share [Abstract]

BASIC AND DILUTED NET INCOME (LOSS) PER SHARE

Basic net income (loss) per share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding. Diluted net income (loss) per share is computed by dividing net income (loss) by the weighted-average number of dilutive common shares outstanding during the period. Diluted shares outstanding is calculated by adding to the weighted shares outstanding any potential (unissued) shares of common stock from outstanding stock options and warrants based on the treasury stock method, as well as weighted shares outstanding of any potential (unissued) shares of common stock from restricted stock units. In periods when a net loss is reported, all common stock equivalents are excluded from the calculation because they would have an anti-dilutive effect, meaning the loss per share would be reduced. Therefore, in periods when a loss is reported, there is no difference in basic and dilutive loss per share. Common stock equivalents include stock options, restricted stock awards and warrants.

The number of shares of potentially dilutive common stock presented on a weighted average basis, related to options, restricted stock units and warrants (prior to consideration of the treasury stock method) that were excluded from the calculation of dilutive shares since the inclusion of such shares would be anti-dilutive for the three months ended March 31, 2019 and March 31, 2018, respectively, are shown below. Issued and outstanding warrants shown in the table below are described in greater detail in Note 11, contained herein.



	Three Months Ended March 31,
	2019	2018
Options	1,720,367	700,722
Restricted stock units	7,101	14,259
Warrants	7,433,084	10,597,486
Total	9,160,552	11,312,467

INVESTMENTS (Notes)

3 Months Ended

Mar. 31, 2019

Investments, Debt and Equity Securities [Abstract]

INVESTMENTS

Investments consist of the following:



	Accumulated Cost		Unrealized				Market Value
December 31, 2018	Accumulated Cost		Gain		(Loss)		Market Value
Short-term investments
Government securities	$	2,746	$	—	$	—	$	2,746
Total	$	2,746	$	—	$	—	$	2,746

There were no long or short-term investments at March 31, 2019, and no long-term investments at December 31, 2018.

FAIR VALUE MEASUREMENTS

3 Months Ended

Mar. 31, 2019

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

The Company has certain financial assets recorded at fair value which have been classified as either Level 1 or 2 within the fair value hierarchy as described in the accounting standards for fair value measurements. Fair value is the price that would be received from the sale of an asset or the price paid to transfer a liability in an orderly transaction between independent market participants at the measurement date. Fair values determined by Level 1 inputs utilize observable data such as quoted prices in active markets. Fair values determined by Level 2 inputs utilize data points other than quoted prices in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, which require the reporting entity to develop its own assumptions. The fair value hierarchy level is determined by the lowest level of significant input. At March 31, 2019 and December 31, 2018, the Company did not own any Level 3 financial assets.

The Company’s financial assets classified as Level 2 at March 31, 2019 and December 31, 2018, were initially valued at the transaction price and subsequently valued utilizing third party pricing services. Because the Company’s investment portfolio may include securities that do not always trade on a daily basis, the pricing services use many observable market inputs to determine value including reportable trades, benchmark yields and benchmarking of like securities. The Company validates the prices provided by the third party pricing services by reviewing their pricing methods and obtaining market values from other pricing sources. After completing the validation procedures, the Company did not adjust or override any fair value measurements provided by these pricing services as of March 31, 2019 and December 31, 2018.

The tables below present information about the Company’s assets that are measured at fair value on a recurring basis as of March 31, 2019 and December 31, 2018 and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value.



	Fair value measurements at reporting date using
	Quoted prices in active markets for identical assets		Significant other observable inputs		Significant unobservable inputs		Balance as of
Description	(Level 1)		(Level 2)		(Level 3)		March 31, 2019
Cash equivalents:
Money market funds	$	5,340	$	—	$	—	$	5,340
U.S. government and agency securities	—		500		—		500
Short-term investments:
U.S. government and agency securities	—		—		—		—
Total	$	5,340	$	500	$	—	$	5,840



	Fair value measurements at reporting date using
	Quoted prices in active markets for identical assets		Significant other observable inputs		Significant unobservable inputs		Balance as of
Description	(Level 1)		(Level 2)		(Level 3)		December 31, 2018
Cash equivalents:
Money market funds	$	2,663	$	—	$	—	$	2,663
Short-term investments:
U.S. government agency securities	—		2,746		—		2,746
Total	$	2,663	$	2,746	$	—	$	5,409

There were no transfers of financial assets between category levels for the three months ended March 31, 2019.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

ACCRUED EXPENSES

3 Months Ended

Mar. 31, 2019

Payables and Accruals [Abstract]

ACCRUED EXPENSES

Accrued expenses consisted of the following at:



	March 31, 2019		December 31, 2018
Employee compensation and benefits	$	140	$	98
Leased facilities	51		50
Professional services	262		234
Other	168		298
Total accrued expenses	$	621	$	680

STOCK-BASED COMPENSATION

3 Months Ended

Mar. 31, 2019

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

STOCK-BASED COMPENSATION

Expense Information for Employee and Non-Employee Stock Awards

The Company recognized stock-based compensation expense related to stock awards, including awards to non-employees and members of the Board of Directors of $162 and $281 for the three months ended March 31, 2019 and March 31, 2018, respectively. At March 31, 2019, there was approximately $1,034 of pre-tax stock-based compensation expense related to unvested awards not yet recognized.

The compensation expense related to unvested stock options is expected to be recognized over a remaining weighted average period of 3.10 years.

Stock Options

A summary of option activity for the three months ended March 31, 2019 is as follows:



	Number of Shares		Weighted Average Exercise Price
Outstanding at December 31, 2018	1,745,037		$	6.38
Granted	21,304		$	1.11
Exercised	—		—
Forfeited	(7,500	)	$	1.43
Expired	(62	)	$	1.65
Outstanding at March 31, 2019	1,758,779		$	6.34

Options vested and expected to vest at March 31, 2019	1,758,779		$	6.34
Options exercisable at March 31, 2019	959,047		$	10.26

Restricted Stock Units

The Company records stock compensation expense for restricted stock units ("RSUs") on a straight line basis over their vesting period based on each RSU's award date market value. The Company pays minimum required income tax withholding associated with RSUs for its employees. As the RSUs vest, the Company withholds a number of shares with an aggregate fair market value equal to the minimum tax withholding amount (unless the employee makes other arrangements for payment of the tax withholding) from the common stock issuable at the vest date. During the three months ended March 31, 2019 and March 31, 2018, no outstanding RSUs vested and therefore the Company did not pay for income tax withholdings associated with RSUs during these periods.

A summary of RSU activity for the three months ended March 31, 2019 is as follows:



	Number of RSUs	Weighted Average Remaining Contractual Life (years)
Outstanding at December 31, 2018	7,101
Awarded	—
Common stock issued upon vesting	—
Forfeited	—
Outstanding at March 31, 2019	7,101	—

Weighted average remaining recognition period (years)	—

LEASES

3 Months Ended

Mar. 31, 2019

Leases [Abstract]

LEASES

New Lease Accounting

Topic 842 is effective for annual reporting periods beginning after December 15, 2018 and for interim periods within those fiscal years. The Company adopted Topic 842 on January 1, 2019 and elected to apply the new lease accounting requirements to its financial statements beginning on January 1, 2018 (the earliest period presented in its comparative financial statements), using a modified retrospective approach. The new guidance also requires additional financial statement disclosures to enable users of financial statements to better assess the amount, timing, and uncertainty of cash flows arising from leases. Topic 842 replaces the previous lease accounting and reporting guidance of ASC Topic 840, Leases, ("ASC Topic 840") and requires lessees to reflect a right-of-use asset and a lease liability on their balance sheet for leases with terms of more than twelve months.

The Company's enactment of Topic 842 effective on January 1, 2019, resulted in it recording right-of-use assets and lease liabilities for real estate and equipment leases of $4,766 and $6,465, respectively. The Company also eliminated $1,005 in lease incentive obligations from its balance sheet on January 1, 2019 as a result of the discontinuation of the previous guidance under ASC Topic 840. Application of the new pronouncement to the Company's 2018 comparative year had a material effect on its previously issued 2018 financial statements. The Company's condensed consolidated balance sheet as of December 31, 2018 and its condensed consolidated statements of operations, comprehensive income (loss), cash flows and stockholders' equity for the three months ending March 31, 2018, included herein, have been adjusted to incorporate the guidance of Topic 842. Adjustments to 2018 operating expenses for the three and twelve months ending March 31, 2018 and December 31, 2018 as a result of implementing Topic 842, as shown in the tables below, were immaterial.

Under Topic 842, leases are classified as either operating or finance leases, with classification based on criteria similar to previous lease accounting guidance, but without the explicit quantitative determining factors used to establish a lease as either a capital or an operating lease. The Company reviewed its 2018 transitional leases and its currently active leases falling within the scope of Topic 842 and determined that all of its leases met the criteria for classification as operating leases.

Lease liabilities are recorded as of their commencement date and are calculated as the present value of the remaining lease payments, using the interest rate implicit in the lease, or if that rate is not readily determinable, using the lessee's incremental borrowing rate. Right-of-use assets are equal to the lease liability with adjustments made, as necessary, for lease prepayments, accruals, initial direct costs, lessor lease incentives and any lease impairments that may be present. Topic 842 further requires that lease expense for operating leases be calculated on a straight-line basis and reported as a single operating expense within income from continuing operations.

Topic 842 provides a number of transitional expedients designed to assist lessees with initial implementation. The Company made the following elections in applying Topic 842.


•	Short-term lease exception. Active leases as of January 1, 2018, and new leases entered into thereafter with terms of twelve months or less were and will be excluded from accounting under Topic 842.

•

Package of practical expedients. These expedients, which must be elected in their entirety, permit a company to continue its historical accounting during the transition period for contractual arrangements containing embedded leases in lieu of performing a re-evaluation of the agreements in order to separate lease and nonlease components. The expedients also permit a company to maintain its previous accounting classification for transitional leases as either operating or finance leases without reassessment under the new guidance. Lastly, the package of practical expedients does not require reassessment and capitalization of initial direct costs incurred to establish a lease.

In applying the guidance of Topic 842 to the 2018 transition period, the Company did not elect the available hindsight expedient with respect to the determination of lease terms used in the calculation of lease liabilities and right-of-use assets by considering the actual outcome of lease renewals.

Maturity Analysis of Lease Liabilities

At March 31, 2019, the Company's lease liabilities will mature as follows:



Year ended December 31,	Undiscounted Cash Flows
2019 (April to December)	$	948
2020	1,080
2021	939
2022	969
2023	998
Thereafter	3,082
Total undiscounted future lease payments	8,016
Discount	(1,749		)
Total lease liabilities	$	6,267
Short-term lease liabilities	$	869
Long-term lease liabilities	$	5,398

At March 31, 2019, real estate and equipment leases represent approximately 99% and 1% , of the Company's lease liabilities, respectively.

Quantitative Disclosure of Lease Costs



	Three Months Ended March 31,
	2019			2018
Lease cost:
Operating lease cost	$	259		$	266
Short-term lease cost	146			118
Sublease income	(124		)	(119		)
Total lease cost, net	$	281		$	265

Other information:
Weighted-average remaining lease term (years)	7.2			7.4
Weighted-average discount rate	6.75%			6.75%

Impact of Topic 842 Adoption on Reported Results

Adoption of the new lease standard impacted the Company's 2018 reported financial statements as follows:



	Three Months Ended March 31, 2018
	As Reported			New Lease Standard Adjustment			As Adjusted
Condensed Consolidated Statements of Income:
Revenue	$	60		$	—		$	60
Expenses	2,367			10			2,377
Other Income (expense)	17			8			25
Net loss	(2,290		)	(2		)	(2,292		)
Basic and diluted net loss per share	(0.24		)	—			(0.24		)



	Year Ended December 31, 2018
	As Reported			New Lease Standard Adjustment			As Adjusted
Condensed Consolidated Statements of Income:
Revenue	$	556		$	—		$	556
Expenses	9,830			45			9,875
Other Income (expense)	104			30			134
Net loss	(9,170		)	(15		)	(9,185		)
Basic and diluted net loss per share	(0.92		)	—			(0.92		)



	March 31, 2018
	As Reported		New Lease Standard Adjustment			As Adjusted
Condensed Consolidated Balance Sheet:
Current assets:	$	12,094	$	—		$	12,094
Restricted cash	317		—			317
Property and equipment, net	1,526		—			1,526
Right-of-use assets	—		5,294			5,294
Other assets	103		—			103
Total assets	$	14,040	$	5,294		$	19,334

Liabilities and Stockholders' Equity:
Accounts payable	$	80	$	—		$	80
Accrued expenses	1,352		(564		)	788
Short-term lease liabilities	—		684			684
Lease incentive obligation, net of current portion	973		(973		)	—
Long-term lease liabilities	—		6,149			6,149
Stockholders' equity	11,635		(2		)	11,633
Total liabilities and stockholders' equity	$	14,040	$	5,294		$	19,334



	December 31, 2018
	As Reported		New Lease Standard Adjustment			As Adjusted
Condensed Consolidated Balance Sheet:
Current assets:	$	6,377	$	—		$	6,377
Restricted cash	332		—			332
Property and equipment, net	1,385		—			1,385
Right-of-use assets	—		4,766			4,766
Other assets	100		—			100
Total assets	$	8,194	$	4,766		$	12,960

Liabilities and Stockholders' Equity:
Accounts payable	$	117	$	—		$	117
Accrued expenses	1,429		(749		)	680
Short-term lease liabilities	—		844			844
Lease incentive obligation, net of current portion	935		(935		)	—
Long-term lease liabilities	—		5,621			5,621
Stockholders' equity	5,713		(15		)	5,698
Total liabilities and stockholders' equity	$	8,194	$	4,766		$	12,960

Real Estate Leases

During 2016 the Company entered into a lease agreement for its headquarters, pursuant to which the Company leases approximately 29,622 square feet of office and research and development space located at 19 Presidential Way, Woburn, Massachusetts. The lease began on June 1, 2016 and will end on November 30, 2026. The lease agreement does not include any options for the early termination or the extension of the lease. The Company provided the landlord with a security deposit in the form of a letter of credit in the amount of $307. Pursuant to the lease, the Company will also pay certain taxes and operating costs associated with the premises throughout the term of the lease. During the buildout of the rented space, the landlord paid $889 for tenant improvements to the facility and an additional $444 for tenant improvements that result in increased rental payments by the Company. Upon the adoption of Topic 842, these improvements were recorded as a reduction of the right-of-use asset.

In October 2016, the Company entered into a sublease agreement with a subsidiary of CJ CheilJedang Corporation ("CJ") with respect to CJ's sublease of approximately 9,874 square feet of its leased facility located in Woburn, Massachusetts. The sublease space was determined to be in excess of the Company's needs. The sublease is coterminous with the Company's master lease and CJ will pay rent and operating expenses equal to approximately one-third of the amounts payable to the landlord by the Company, as adjusted from time-to-time in accordance with the terms of the master lease. Future CJ sublease payments have not been presented as an offset to total undiscounted future lease payments of $8,016 shown in the lease maturity analysis table above. CJ provided the Company with a security deposit of $103 in the form of an irrevocable letter of credit.

The Company also leases approximately 13,702 square feet of office and laboratory space at 650 Suffolk Street, Lowell, Massachusetts. The lease for this facility, as amended, expires in May 2020. The terms of the agreement provide the Company with a five-year option to extend the lease provided written notice is given prior to August 31, 2019. The Company does not intend to elect this option. During July 2018, the Company discontinued further use of the Lowell space, and as a result, the Company recorded a non-cash lease exit charge of $255 for the facility in accordance with ASC Topic 420-10, Exit or Disposal Obligations. The exit charge was recorded as an increase in the Company's lease expense and a reduction to the associated right-of-use asset. The Company will continue to make monthly rental payments for the Lowell facility through its expiration in May 2020.

The Company's wholly-owned subsidiary, Metabolix Oilseeds, Inc. ("MOI"), located in Saskatoon, Saskatchewan, Canada, leases approximately 6,200 square feet of office, laboratory and greenhouse space located within Innovation Place at 410 Downey Road and within the research facility of National Research Council Canada located at 110 Gymnasium Place. None of the leases contain renewal or early termination options. MOI's leases for these facilities expire at various times between April 2019 and May 2020.

COMMITMENTS	3 Months Ended
COMMITMENTS	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS	COMMITMENTS Litigation From time-to-time, the Company may be subject to legal proceedings and claims in the ordinary course of business. The Company is not currently aware of any such proceedings or claims that it believes will have, individually or in the aggregate, a material adverse effect on its business, financial condition or results of operations. Guarantees As of March 31, 2019 and December 31, 2018, the Company did not have significant liabilities recorded for guarantees. The Company enters into indemnification provisions under various agreements with other companies in the ordinary course of business, typically with business partners, contractors, and customers. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of its activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. However, to date Yield10 Bioscience has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of the indemnifications under these agreements is believed to be minimal. Accordingly, the Company has no liabilities recorded for these agreements as of March 31, 2019 and December 31, 2018.

GEOGRAPHIC INFORMATION

3 Months Ended

Mar. 31, 2019

Segment Reporting [Abstract]

GEOGRAPHIC INFORMATION

The geographic distribution of the Company’s grant revenues and long-lived assets are summarized in the tables below:



	U.S.		Canada		Eliminations			Total
Three Months Ended March 31, 2019:
Grant revenue from external customers	$	124	$	—	$	—		$	124
Inter-geographic revenues	—		337		(337		)	—
Revenues	$	124	$	337	$	(337	)	$	124

Three Months Ended March 31, 2018:
Grant revenue from external customers	$	60	$	—	$	—		$	60
Inter-geographic revenues	—		268		(268		)	—
Revenues	$	60	$	268	$	(268	)	$	60

Foreign revenue is based on the country in which the Company’s subsidiary that earned the revenue is domiciled. During the three months ended March 31, 2019, the Company's grant revenue from the Michigan State University sub-award of $124 represented 100% of the revenue reported for the period. During the three months ended March 31, 2018, revenue earned from the U.S. Department of Energy Camelina grant totaled $60, and represented 100% of total revenue for the period.

The geographic distribution of the Company’s long-lived assets is summarized as follows:



	U.S.		Canada		Eliminations		Total
March 31, 2019	$	1,323	$	12	$	—	$	1,335
December 31, 2018	$	1,372	$	13	$	—	$	1,385

CAPITAL STOCK

3 Months Ended

Mar. 31, 2019

Stockholders' Equity Note [Abstract]

CAPITAL STOCK

Common Stock

On March 18, 2019, the Company completed a registered direct offering of its common stock. Proceeds from the transaction were approximately $2,932, before issuance costs of $349. Investors participating in the transaction purchased a total of 2,421,662 shares of common stock at a price of $1.2101 per share.

Preferred Stock

The Company's Certificate of Incorporation authorizes it to issue up to 5,000,000 shares of $0.01 par value preferred stock.

In December 2017, the Company closed on a public offering of its securities that included issuance of 3,987 shares of Series A Convertible Preferred Stock. Each preferred share was convertible, at the holder's option, into 445 shares of common stock at a conversion price of $2.25 per share. As of March 19, 2018, all of the 3,987 preferred shares had been converted to an aggregate of 1,772,000 shares of common stock. When converted, the shares of converted Series A Convertible Preferred Stock were restored to the status of authorized but unissued shares of preferred stock, subject to reissuance by the Board of Directors.

Warrants

The following table summarizes information with regard to outstanding warrants to purchase common stock as of March 31, 2019:



Issuance	Number of Shares Issuable Upon Exercise of Outstanding Warrants	Exercise Price		Expiration Date
June 2015 Private Placement	393,300	$	39.80	June 15, 2019
July 2017 Registered Direct Offering	570,784	$	5.04	January 7, 2024
December 2017 Public Offering - Series A	6,439,000	$	2.25	December 21, 2022
Consultant	30,000	$	2.90	September 11, 2024
Total	7,433,084

Reserved Shares

The following shares of common stock were reserved for future issuance upon exercise of stock options, release of RSUs and conversion of warrants:



	March 31, 2019	December 31, 2018
Stock Options	1,758,779	1,745,037
RSUs	7,101	7,101
Warrants	7,433,084	7,433,084
Total number of common shares reserved for future issuance	9,198,964	9,185,222

ACCOUNTING POLICIES (Policies)	3 Months Ended
ACCOUNTING POLICIES (Policies)	Mar. 31, 2019
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The Company's condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions were eliminated, including transactions with its Canadian subsidiary, Metabolix Oilseeds, Inc.
Cash, Cash Equivalents and Restricted Cash	Cash, Cash Equivalents and Restricted Cash The Company considers all highly liquid investments purchased with an original maturity date of ninety days or less at the date of purchase to be cash equivalents.
Investments	Investments The Company considers all investments purchased with an original maturity date of more than ninety days at the date of purchase and a maturity date of one year or less at the balance sheet date to be short-term investments. All other investments are classified as long-term. The Company held no short or long-term investments at March 31, 2019 and no long-term investments at December 31, 2018. Other-than-temporary impairments of equity investments are recognized in the Company's statements of operations if the Company has experienced a credit loss and has the intent to sell the investment or if it is more likely than not that the Company will be required to sell the investment before recovery of the amortized cost basis. Realized gains and losses, dividends, interest income and declines in value judged to be other-than-temporary credit losses are included in other income (expense). Any premium or discount arising at purchase is amortized and/or accreted to interest income.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of grant revenue and expenses during the reporting periods. Actual results could differ from those estimates.
Foreign Currency Translation	Foreign Currency Translation Foreign denominated assets and liabilities of the Company's wholly owned foreign subsidiaries are translated into U.S. dollars at the prevailing exchange rates in effect on the balance sheet date. Revenues and expenses are translated at average exchange rates prevailing during the period. Any resulting translation gains or losses are recorded in accumulated other comprehensive income (loss) in the consolidated balance sheet. When the Company dissolves, sells or substantially sells all of the assets of a consolidated foreign subsidiary, the cumulative translation gain or loss of that subsidiary is released from comprehensive income (loss) and included within its consolidated statement of operations during the fiscal period when the dissolution or sale occurs.
Income Taxes	Income Taxes The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company's tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is provided to reduce the deferred tax asset to a level which, more likely than not, will be realized.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and investments. The Company has historically invested its cash equivalents in highly rated money market funds, corporate debt, federal agency notes and U.S. treasury notes. Investments, when purchased, are acquired in accordance with the Company’s investment policy which establishes a concentration limit per issuer.

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References + Details

- Definition

Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.

+ References + Details

ACCOUNTING POLICIES (Tables)

3 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Schedule of Restricted Cash and Cash Equivalents

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's Condensed Consolidated Unaudited Balance Sheets included herein:



	March 31, 2019		December 31, 2018
Cash and cash equivalents	$	6,065	$	3,023
Restricted cash	332		332
Total cash, cash equivalents and restricted cash	$	6,397	$	3,355

Schedule of Cash and Cash Equivalents

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's Condensed Consolidated Unaudited Balance Sheets included herein:



	March 31, 2019		December 31, 2018
Cash and cash equivalents	$	6,065	$	3,023
Restricted cash	332		332
Total cash, cash equivalents and restricted cash	$	6,397	$	3,355

BASIC AND DILUTED NET INCOME (LOSS) PER SHARE (Tables)

3 Months Ended

Mar. 31, 2019

Earnings Per Share [Abstract]

Schedule of number of shares of potentially dilutive common stock related to options and warrants that were excluded from the calculation of dilutive shares



	Three Months Ended March 31,
	2019	2018
Options	1,720,367	700,722
Restricted stock units	7,101	14,259
Warrants	7,433,084	10,597,486
Total	9,160,552	11,312,467

INVESTMENTS (Tables)

3 Months Ended

Mar. 31, 2019

Investments, Debt and Equity Securities [Abstract]

Schedule of investment holdings

Investments consist of the following:



	Accumulated Cost		Unrealized				Market Value
December 31, 2018	Accumulated Cost		Gain		(Loss)		Market Value
Short-term investments
Government securities	$	2,746	$	—	$	—	$	2,746
Total	$	2,746	$	—	$	—	$	2,746

FAIR VALUE MEASUREMENTS (Tables)

3 Months Ended

Mar. 31, 2019

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]



	Fair value measurements at reporting date using
	Quoted prices in active markets for identical assets		Significant other observable inputs		Significant unobservable inputs		Balance as of
Description	(Level 1)		(Level 2)		(Level 3)		March 31, 2019
Cash equivalents:
Money market funds	$	5,340	$	—	$	—	$	5,340
U.S. government and agency securities	—		500		—		500
Short-term investments:
U.S. government and agency securities	—		—		—		—
Total	$	5,340	$	500	$	—	$	5,840



	Fair value measurements at reporting date using
	Quoted prices in active markets for identical assets		Significant other observable inputs		Significant unobservable inputs		Balance as of
Description	(Level 1)		(Level 2)		(Level 3)		December 31, 2018
Cash equivalents:
Money market funds	$	2,663	$	—	$	—	$	2,663
Short-term investments:
U.S. government agency securities	—		2,746		—		2,746
Total	$	2,663	$	2,746	$	—	$	5,409

ACCRUED EXPENSES (Tables)

3 Months Ended

Mar. 31, 2019

Payables and Accruals [Abstract]

Schedule of accrued expenses

Accrued expenses consisted of the following at:



	March 31, 2019		December 31, 2018
Employee compensation and benefits	$	140	$	98
Leased facilities	51		50
Professional services	262		234
Other	168		298
Total accrued expenses	$	621	$	680

STOCK-BASED COMPENSATION (Tables)

3 Months Ended

Mar. 31, 2019

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Summary of option activity

A summary of option activity for the three months ended March 31, 2019 is as follows:



	Number of Shares		Weighted Average Exercise Price
Outstanding at December 31, 2018	1,745,037		$	6.38
Granted	21,304		$	1.11
Exercised	—		—
Forfeited	(7,500	)	$	1.43
Expired	(62	)	$	1.65
Outstanding at March 31, 2019	1,758,779		$	6.34

Options vested and expected to vest at March 31, 2019	1,758,779		$	6.34
Options exercisable at March 31, 2019	959,047		$	10.26

Schedule of restricted stock units activity

A summary of RSU activity for the three months ended March 31, 2019 is as follows:



	Number of RSUs	Weighted Average Remaining Contractual Life (years)
Outstanding at December 31, 2018	7,101
Awarded	—
Common stock issued upon vesting	—
Forfeited	—
Outstanding at March 31, 2019	7,101	—

Weighted average remaining recognition period (years)	—

LEASES (Tables)

3 Months Ended

Mar. 31, 2019

Leases [Abstract]

Maturity analysis of lease liabilities

At March 31, 2019, the Company's lease liabilities will mature as follows:



Year ended December 31,	Undiscounted Cash Flows
2019 (April to December)	$	948
2020	1,080
2021	939
2022	969
2023	998
Thereafter	3,082
Total undiscounted future lease payments	8,016
Discount	(1,749		)
Total lease liabilities	$	6,267
Short-term lease liabilities	$	869
Long-term lease liabilities	$	5,398

Quantitative disclosure of lease costs



	Three Months Ended March 31,
	2019			2018
Lease cost:
Operating lease cost	$	259		$	266
Short-term lease cost	146			118
Sublease income	(124		)	(119		)
Total lease cost, net	$	281		$	265

Other information:
Weighted-average remaining lease term (years)	7.2			7.4
Weighted-average discount rate	6.75%			6.75%

Impact of Topic 842 adoption on reported results

Adoption of the new lease standard impacted the Company's 2018 reported financial statements as follows:



	Three Months Ended March 31, 2018
	As Reported			New Lease Standard Adjustment			As Adjusted
Condensed Consolidated Statements of Income:
Revenue	$	60		$	—		$	60
Expenses	2,367			10			2,377
Other Income (expense)	17			8			25
Net loss	(2,290		)	(2		)	(2,292		)
Basic and diluted net loss per share	(0.24		)	—			(0.24		)



	Year Ended December 31, 2018
	As Reported			New Lease Standard Adjustment			As Adjusted
Condensed Consolidated Statements of Income:
Revenue	$	556		$	—		$	556
Expenses	9,830			45			9,875
Other Income (expense)	104			30			134
Net loss	(9,170		)	(15		)	(9,185		)
Basic and diluted net loss per share	(0.92		)	—			(0.92		)



	March 31, 2018
	As Reported		New Lease Standard Adjustment			As Adjusted
Condensed Consolidated Balance Sheet:
Current assets:	$	12,094	$	—		$	12,094
Restricted cash	317		—			317
Property and equipment, net	1,526		—			1,526
Right-of-use assets	—		5,294			5,294
Other assets	103		—			103
Total assets	$	14,040	$	5,294		$	19,334

Liabilities and Stockholders' Equity:
Accounts payable	$	80	$	—		$	80
Accrued expenses	1,352		(564		)	788
Short-term lease liabilities	—		684			684
Lease incentive obligation, net of current portion	973		(973		)	—
Long-term lease liabilities	—		6,149			6,149
Stockholders' equity	11,635		(2		)	11,633
Total liabilities and stockholders' equity	$	14,040	$	5,294		$	19,334



	December 31, 2018
	As Reported		New Lease Standard Adjustment			As Adjusted
Condensed Consolidated Balance Sheet:
Current assets:	$	6,377	$	—		$	6,377
Restricted cash	332		—			332
Property and equipment, net	1,385		—			1,385
Right-of-use assets	—		4,766			4,766
Other assets	100		—			100
Total assets	$	8,194	$	4,766		$	12,960

Liabilities and Stockholders' Equity:
Accounts payable	$	117	$	—		$	117
Accrued expenses	1,429		(749		)	680
Short-term lease liabilities	—		844			844
Lease incentive obligation, net of current portion	935		(935		)	—
Long-term lease liabilities	—		5,621			5,621
Stockholders' equity	5,713		(15		)	5,698
Total liabilities and stockholders' equity	$	8,194	$	4,766		$	12,960

GEOGRAPHIC INFORMATION (Tables)

3 Months Ended

Mar. 31, 2019

Segment Reporting [Abstract]

Schedule of the geographic distribution of revenues and long-lived assets from continuing operations

The geographic distribution of the Company’s grant revenues and long-lived assets are summarized in the tables below:



	U.S.		Canada		Eliminations			Total
Three Months Ended March 31, 2019:
Grant revenue from external customers	$	124	$	—	$	—		$	124
Inter-geographic revenues	—		337		(337		)	—
Revenues	$	124	$	337	$	(337	)	$	124

Three Months Ended March 31, 2018:
Grant revenue from external customers	$	60	$	—	$	—		$	60
Inter-geographic revenues	—		268		(268		)	—
Revenues	$	60	$	268	$	(268	)	$	60

Schedule of the geographic distribution of long-lived assets

The geographic distribution of the Company’s long-lived assets is summarized as follows:



	U.S.		Canada		Eliminations		Total
March 31, 2019	$	1,323	$	12	$	—	$	1,335
December 31, 2018	$	1,372	$	13	$	—	$	1,385

CAPITAL STOCK (Tables)

3 Months Ended

Mar. 31, 2019

Stockholders' Equity Note [Abstract]

Schedule of stockholders' equity note, warrants or rights

The following table summarizes information with regard to outstanding warrants to purchase common stock as of March 31, 2019:



Issuance	Number of Shares Issuable Upon Exercise of Outstanding Warrants	Exercise Price		Expiration Date
June 2015 Private Placement	393,300	$	39.80	June 15, 2019
July 2017 Registered Direct Offering	570,784	$	5.04	January 7, 2024
December 2017 Public Offering - Series A	6,439,000	$	2.25	December 21, 2022
Consultant	30,000	$	2.90	September 11, 2024
Total	7,433,084

Schedule of Stock by Class

The following shares of common stock were reserved for future issuance upon exercise of stock options, release of RSUs and conversion of warrants:



	March 31, 2019	December 31, 2018
Stock Options	1,758,779	1,745,037
RSUs	7,101	7,101
Warrants	7,433,084	7,433,084
Total number of common shares reserved for future issuance	9,198,964	9,185,222

- Definition

Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Unrestricted cash and cash equivalents	$ 6,065	$ 3,023

ACCOUNTING POLICIES (Details) - USD ($) $ in Thousands	3 Months Ended
ACCOUNTING POLICIES (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2018
Concentration of credit risk
Restricted cash	$ 332	$ 332	$ 317
Government Grants
Concentration of credit risk
Receivables/sales (as a percent)	100.00%
Unbilled receivables	$ 124

ACCOUNTING POLICIES - Schedule of Cash And Restricted Cash (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Cash and cash equivalents	$ 6,065	$ 3,023
Restricted cash	332	332	$ 317
Total cash, cash equivalents and restricted cash	$ 6,397	$ 3,355	$ 7,900	$ 14,804

BASIC AND DILUTED NET INCOME (LOSS) PER SHARE (Details) - shares	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares	9,160,552	11,312,467
Options
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares	1,720,367	700,722
Restricted stock units
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares	7,101	14,259
Warrants
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares	7,433,084	10,597,486

INVESTMENTS (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Short-term Investments [Abstract]
Accumulated Cost		$ 2,746,000
Unrealized Gain		0
Unrealized (Loss)		0
Market Value	$ 0	2,746,000
Long-term Investments	$ 0	0
Government securities
Short-term Investments [Abstract]
Accumulated Cost		2,746,000
Unrealized Gain		0
Unrealized (Loss)		0
Market Value		$ 2,746,000

FAIR VALUE MEASUREMENTS (Details) - Fair Value, measurements, recurring - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Fair value measurements
Assets, fair value disclosure	$ 5,840	$ 5,409
Money market funds
Fair value measurements
Assets, fair value disclosure	5,340	2,663
U.S. government and agency securities
Fair value measurements
Assets, fair value disclosure	500
Short-term Investments: U.S. government and agency securities
Fair value measurements
Assets, fair value disclosure	0	2,746
Quoted prices in active markets for identical assets
Fair value measurements
Assets, fair value disclosure	5,340	2,663
Quoted prices in active markets for identical assets \| Money market funds
Fair value measurements
Assets, fair value disclosure	5,340	2,663
Quoted prices in active markets for identical assets \| U.S. government and agency securities
Fair value measurements
Assets, fair value disclosure	0
Quoted prices in active markets for identical assets \| Short-term Investments: U.S. government and agency securities
Fair value measurements
Assets, fair value disclosure	0	0
Significant other observable inputs
Fair value measurements
Assets, fair value disclosure	500	2,746
Significant other observable inputs \| Money market funds
Fair value measurements
Assets, fair value disclosure	0	0
Significant other observable inputs \| U.S. government and agency securities
Fair value measurements
Assets, fair value disclosure	500
Significant other observable inputs \| Short-term Investments: U.S. government and agency securities
Fair value measurements
Assets, fair value disclosure	0	2,746
Significant unobservable inputs
Fair value measurements
Assets, fair value disclosure	0	0
Significant unobservable inputs \| Money market funds
Fair value measurements
Assets, fair value disclosure	0	0
Significant unobservable inputs \| U.S. government and agency securities
Fair value measurements
Assets, fair value disclosure	0
Significant unobservable inputs \| Short-term Investments: U.S. government and agency securities
Fair value measurements
Assets, fair value disclosure	$ 0	$ 0

ACCRUED EXPENSES (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2018
Payables and Accruals [Abstract]
Employee compensation and benefits	$ 140	$ 98
Leased facilities	51	50
Professional services	262	234
Other	168	298
Total accrued expenses	$ 621	$ 680	$ 788

STOCK-BASED COMPENSATION (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Stock-based compensation
Stock-based compensation	$ 162	$ 281
Employee stock option
Stock-based compensation
Stock-based compensation expense, net of estimated forfeitures, related to unvested awards not yet recognized	$ 1,034
Weighted average remaining recognition period (years)	3 years 1 month 7 days
Options
Number of Shares
Outstanding at the beginning of the period (in shares)	1,745,037
Granted (in shares)	21,304
Exercised (in shares)	0
Forfeited (in shares)	(7,500)
Expired (in shares)	(62)
Outstanding at the end of the period (in shares)	1,758,779
Options vested and expected to vest at the end of the period (in shares)	1,758,779
Options exercisable at the end of the period (in shares)	959,047
Weighted Average Exercise Price
Outstanding at the beginning of the period (in dollars per share)	$ 6.38
Granted (in dollars per share)	1.11
Exercised (in dollars per share)	0.00
Forfeited (in dollars per share)	1.43
Expired (in dollars per share)	1.65
Outstanding at the end of the period (in dollars per share)	6.34
Options vested and expected to vest at the end of the period (in dollars per share)	6.34
Options exercisable at the end of the period (in dollars per share)	$ 10.26

STOCK-BASED COMPENSATION - RESTRICTED STOCK UNIT ACTIVITY TABLE (Details) - Restricted stock units	3 Months Ended
	Mar. 31, 2019 shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Outstanding (in shares)	7,101
Awarded (in shares)	0
Common stock issued upon vesting (in shares)	0
Forfeited (in shares)	0
Outstanding (in shares)	7,101

LEASES - Narrative (Details) $ in Thousands		1 Months Ended	12 Months Ended
LEASES - Narrative (Details) $ in Thousands	Jan. 01, 2019 USD ($)	Jul. 31, 2018 USD ($)	Dec. 31, 2016 USD ($) ft²	Mar. 31, 2019 USD ($) ft²	Dec. 31, 2018 USD ($)	Mar. 31, 2018 USD ($)	Oct. 31, 2016 USD ($) ft²
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Right-of-use assets				$ 4,619	$ 4,766	$ 5,294
Lease liabilities				6,267
Area of real estate property \| ft²			29,622
Security deposit			$ 307
Operating leases, landlord reimbursement for lease improvements			889
Operating leases, landlord reimb for lease improvements, additional payments			$ 444
Undiscounted future lease payments				$ 8,016
CJ CheilJedang Corporation
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Area of real estate property \| ft²							9,874
Security deposit							$ 103
650 Suffolk Street
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Area of real estate property \| ft²				13,702
Operating leases, renewal term				5 years
Non-cash lease exit charge		$ 255
Subsidiaries
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Area of real estate property \| ft²				6,200
Topic 842
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Right-of-use assets	$ 4,766
Lease liabilities	6,465
Elimination of lease incentive obligations	$ 1,005
Real estate leases
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percent of lease liabilities				99.00%
Equipment leases
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percent of lease liabilities				1.00%

LEASES - Maturity Analysis of Lease Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2018
Leases [Abstract]
2019 (April to December)	$ 948
2020	1,080
2021	939
2022	969
2023	998
Thereafter	3,082
Total undiscounted future lease payments	8,016
Discount	(1,749)
Total lease liabilities	6,267
Short-term lease liabilities	869	$ 844	$ 684
Long-term lease liabilities	$ 5,398	$ 5,621	$ 6,149

LEASES - Quantitative Disclosure of Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Lease cost:
Operating lease cost	$ 259	$ 266
Short-term lease cost	146	118
Sublease income	(124)	(119)
Total lease cost, net	$ 281	$ 265
Other information:
Weighted-average remaining lease term	7 years 2 months 12 days	7 years 4 months 24 days
Weighted-average discount rate	6.75%	6.75%

LEASES - Impact of Topic 842 Adoption on Reported Results (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Jan. 01, 2019	Dec. 31, 2017
Condensed Consolidated Statements of Income:
Revenue	$ 124	$ 60	$ 556
Expenses	2,409	2,377	9,875
Other Income (expense)	25	25	134
Net loss	$ (2,260)	$ (2,292)	$ (9,185)
Basic and diluted net loss per share (in USD per share)	$ (0.22)	$ (0.24)	$ (0.92)
Condensed Consolidated Balance Sheet:
Current assets	$ 6,738	$ 12,094	$ 6,377
Restricted cash	332	317	332
Property and equipment, net	1,335	1,526	1,385
Right-of-use assets	4,619	5,294	4,766
Other assets	71	103	100
Total assets	13,095	19,334	12,960
Liabilities and Stockholders' Equity:
Accounts payable	12	80	117
Accrued expenses	621	788	680
Lease liabilities	869	684	844
Lease incentive obligation, net of current portion		0	0
Long-term lease liabilities	5,398	6,149	5,621
Stockholders’ equity	6,195	11,633	5,698		$ 13,502
Total liabilities and stockholders’ equity	$ 13,095	19,334	12,960
As Reported
Condensed Consolidated Statements of Income:
Revenue		60	556
Expenses		2,367	9,830
Other Income (expense)		17	104
Net loss		$ (2,290)	$ (9,170)
Basic and diluted net loss per share (in USD per share)		$ (0.24)	$ (0.92)
Condensed Consolidated Balance Sheet:
Current assets		$ 12,094	$ 6,377
Restricted cash		317	332
Property and equipment, net		1,526	1,385
Right-of-use assets		0	0
Other assets		103	100
Total assets		14,040	8,194
Liabilities and Stockholders' Equity:
Accounts payable		80	117
Accrued expenses		1,352	1,429
Lease liabilities		0	0
Lease incentive obligation, net of current portion		973	935
Long-term lease liabilities		0	0
Stockholders’ equity		11,635	5,713
Total liabilities and stockholders’ equity		14,040	8,194
Topic 842
Condensed Consolidated Balance Sheet:
Right-of-use assets				$ 4,766
Topic 842 \| New Lease Standard Adjustment
Condensed Consolidated Statements of Income:
Revenue		0	0
Expenses		10	45
Other Income (expense)		8	30
Net loss		$ (2)	$ (15)
Basic and diluted net loss per share (in USD per share)		$ 0.00	$ 0.00
Condensed Consolidated Balance Sheet:
Current assets		$ 0	$ 0
Restricted cash		0	0
Property and equipment, net		0	0
Right-of-use assets		5,294	4,766
Other assets		0	0
Total assets		5,294	4,766
Liabilities and Stockholders' Equity:
Accounts payable		0	0
Accrued expenses		(564)	(749)
Lease liabilities		684	844
Lease incentive obligation, net of current portion		(973)	(935)
Long-term lease liabilities		6,149	5,621
Stockholders’ equity		(2)	(15)
Total liabilities and stockholders’ equity		$ 5,294	$ 4,766

GEOGRAPHIC INFORMATION - Schedule of distribution of revenues and long-lived assets (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Geographic Information
Revenue	$ 124	$ 60	$ 556
U.S.
Geographic Information
Revenue	124	60
Canada
Geographic Information
Revenue	337	268
Operating segments
Geographic Information
Revenue	124	60
Operating segments \| U.S.
Geographic Information
Revenue	124	60
Operating segments \| Canada
Geographic Information
Revenue	0	0
Eliminations
Geographic Information
Revenue	(337)	(268)
Eliminations \| Canada
Geographic Information
Revenue	$ 337	$ 268

GEOGRAPHIC INFORMATION - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Concentration risk
Revenue	$ 124	$ 60	$ 556
US Department of Energy \| Sales
Concentration risk
Concentration risk (as a percent)	100.00%	100.00%
Grant
Concentration risk
Revenue	$ 124	$ 60
Grant \| US Department of Energy \| Sales
Concentration risk
Revenue	$ 124	$ 60

GEOGRAPHIC INFORMATION - Schedule of geographic distribution (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2018
Geographic Information
Long-lived assets	$ 1,335	$ 1,385	$ 1,526
Reportable Geographical Components \| U.S.
Geographic Information
Long-lived assets	1,323	1,372
Reportable Geographical Components \| Canada
Geographic Information
Long-lived assets	12	13
Eliminations
Geographic Information
Long-lived assets	$ 0	$ 0

CAPITAL STOCK - Common Stock (Details) - Registered direct offering $ / shares in Units, $ in Thousands	Mar. 18, 2019 USD ($) $ / shares shares
Proceeds from stock offering	$ 2,932
Payments of stock issuance costs	$ 349
Common stock sold (in shares) \| shares	2,421,662
Common stock sold, price (in dollars per share) \| $ / shares	$ 1.2101

CAPITAL STOCK - Preferred Stock (Details) - $ / shares		1 Months Ended
CAPITAL STOCK - Preferred Stock (Details) - $ / shares	Mar. 19, 2018	Dec. 31, 2017	Mar. 31, 2019	Dec. 31, 2018
Class of Stock [Line Items]
Preferred stock, authorized (in shares)			5,000,000	5,000,000
Preferred stock, par value per share (in dollars per share)			$ 0.01	$ 0.01
Number of shares issuable upon conversion (in shares)			7,433,084
Stock issued upon conversion of securities (in shares)	1,772,000
Class B Units
Class of Stock [Line Items]
Shares issued during period (in shares)		3,987
Series A Warrant
Class of Stock [Line Items]
Number of shares issuable upon conversion (in shares)		445
Series A Warrant \| Class B Units
Class of Stock [Line Items]
Investment warrants, exercise price (in shares)		$ 2.25

CAPITAL STOCK - Information on outstanding warrants (Details)	Mar. 31, 2019 $ / shares shares
Class of Warrant or Right [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants	7,433,084
June 2015 Private Placement
Class of Warrant or Right [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants	393,300
Exercise price of warrants (in dollars per share) \| $ / shares	$ 39.80
July 2017 Registered Direct Offering
Class of Warrant or Right [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants	570,784
Exercise price of warrants (in dollars per share) \| $ / shares	$ 5.04
Class A Units
Class of Warrant or Right [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants	6,439,000
Exercise price of warrants (in dollars per share) \| $ / shares	$ 2.25
Consultant
Class of Warrant or Right [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants	30,000
Exercise price of warrants (in dollars per share) \| $ / shares	$ 2.90

CAPITAL STOCK - Schedule of common stock reserved for future issuance (Details) - shares	Mar. 31, 2019	Dec. 31, 2018
Class of Stock [Line Items]
Total number of common shares reserved for future issuance	9,198,964	9,185,222
Options
Class of Stock [Line Items]
Total number of common shares reserved for future issuance	1,758,779	1,745,037
Restricted stock units
Class of Stock [Line Items]
Total number of common shares reserved for future issuance	7,101	7,101
Warrants
Class of Stock [Line Items]
Total number of common shares reserved for future issuance	7,433,084	7,433,084